Factors associated with rituximab-mediated B cell depletion in ABO-incompatible adult living donor liver transplantation.
Suk Kyun HongKwang-Woong LeeJae-Yoon KimJaewon LeeJi Young KimHyun Hwa ChoiSu Young HongJeong-Moo LeeYoung Rok ChoiNam-Joon YiKyung-Suk SuhPublished in: Korean journal of transplantation (2023)
There were significant changes in the anti-A/B titers and CD19 levels over time in each patient after ABOi LDLT. The difference in outcomes following LT according to the FcγR SNP type for rituximab was unclear. Further studies with larger sample sizes are needed to confirm the effect of FcγR SNPs on rituximab therapy.